Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...